Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Acquires $112,000.00 in Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Charles W. Newton purchased 200,000 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $0.56 per share, with a total value of $112,000.00. Following the completion of the acquisition, the chief financial officer now owns 200,000 shares of the company’s stock, valued at approximately $112,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Lyell Immunopharma Stock Down 6.5 %

NASDAQ LYEL opened at $0.48 on Wednesday. Lyell Immunopharma, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $3.15. The stock has a market cap of $142.80 million, a price-to-earnings ratio of -0.61 and a beta of -0.41. The business has a fifty day moving average of $0.62 and a 200-day moving average of $0.90.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The business had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. As a group, analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LYEL. Decheng Capital LLC acquired a new position in Lyell Immunopharma during the fourth quarter worth approximately $7,622,000. Foresite Capital Management V LLC acquired a new position in Lyell Immunopharma during the fourth quarter worth approximately $5,205,000. venBio Partners LLC acquired a new position in Lyell Immunopharma during the fourth quarter worth approximately $4,545,000. Renaissance Technologies LLC increased its position in Lyell Immunopharma by 716.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company’s stock worth $1,032,000 after purchasing an additional 1,414,746 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Lyell Immunopharma during the fourth quarter worth approximately $887,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a report on Thursday, March 13th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.